TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28643922

Group type: EXPERIMENTAL
Intervention: 4 kPa stress
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 13 kPa stress
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 26 kPa stress
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 52 kPa stress
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 78 kPa stress
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Growing subjects (G)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Non-growing subjects (NG)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Overall comparison of G vs NG
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Stress magnitude
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Optimal applied stresses
Number of subjects: 46
Study: 26066915

Group type: EXPERIMENTAL
Intervention: Screening, Brief Intervention, and Referral to Treatment (SBIRT)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Assessment alone
Number of subjects: 234
Study: 23350589

Group type: EXPERIMENTAL
Intervention: Corticocancellous allograft block with rhPDGF‐BB
Number of subjects: 16

Group type: COMPARATOR
Intervention: Corticocancellous allograft block with saline solution
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Standard guided bone regeneration with rhPDGF‐BB
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard guided bone regeneration with saline solution
Number of subjects: 16
Study: 22732511

Group type: EXPERIMENTAL
Intervention: Antibiotics plus albumin (1.5 g/kgbw at diagnosis and 1 g/kgbw at day 3); n=56
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Antibiotics plus albumin; n=56
Number of subjects: 110

Group type: COMPARATOR
Intervention: Antibiotics alone; n=54
Number of subjects: 110
Study: 20083527

Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 133

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 133
Study: 16862634

Group type: EXPERIMENTAL
Intervention: Breast cancer health education intervention
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Emotional expression intervention
Number of subjects: 218

Group type: COMPARATOR
Intervention: Standard care control condition
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: All interventions (health education, emotional expression, control)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Secondary analyses
Number of subjects: 218
Study: 16143188

Group type: EXPERIMENTAL
Intervention: Thyroid hormone suppressive therapy (THST)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo or no treatment
Number of subjects: 609

Group type: COMPARATOR
Intervention: Long-term treatment (5 years)
Number of subjects: 609

Group type: COMPARATOR
Intervention: THST withdrawal
Number of subjects: 609
Study: 12403182

Group type: EXPERIMENTAL
Intervention: Active modalities (various treatments)
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: Anterior repositioning appliance therapy
Number of subjects: 2104

Group type: COMPARATOR
Intervention: Flat plane splint therapy
Number of subjects: 2104

Group type: COMPARATOR
Intervention: Untreated TMD patients
Number of subjects: 2104
Study: 10453830

Group type: EXPERIMENTAL
Intervention: Mifepristone 400 mg orally followed by a single oral dose of 400 microg misoprostol 48 hours later (n = 60)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Expectant management (n = 62)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Number of subjects: 122
Study: 7805235

Group type: EXPERIMENTAL
Intervention: Zankiren HCl (10 to 250 mg)
Number of subjects: 24
Study: 2179974

Group type: EXPERIMENTAL
Intervention: amitriptylinoxide
Number of subjects: 32

Group type: COMPARATOR
Intervention: amitriptyline
Number of subjects: 32
Study: 7250172

Group type: EXPERIMENTAL
Intervention: Fixed combination of sotalol and hydrochlorothiazide (6.4:1 ratio)
Number of subjects: 30
Study: 31526257

Group type: EXPERIMENTAL
Intervention: Integrated model including stage, two bone marrow texture features, one tumor with penumbra texture feature, and two penumbra texture features.
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Fully integrated model with pretreatment FDG PET texture features.
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Binary score stratifying patients into high and low risk of poor outcome.
Number of subjects: 227
Study: 28138781

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - additional feedback session based on a knowledge test
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control Group (CG) - routine preoperative patient education only
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both groups (IG and CG)
Number of subjects: 100
Study: 25862350

Group type: EXPERIMENTAL
Intervention: Capecitabine 825 mg/m² twice daily on days 1-21 every 4 weeks
Number of subjects: 142

Group type: COMPARATOR
Intervention: S-1 40-60 mg twice daily on days 1-28 every 6 weeks
Number of subjects: 142

Group type: COMPARATOR
Intervention: S-1
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 142
Study: 23799280

Group type: EXPERIMENTAL
Intervention: VIPON tampon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen (200-400 mg)
Number of subjects: 0
Study: 17594077

Group type: EXPERIMENTAL
Intervention: Specific segmental muscle training program of the lumbar spine (12 weeks duration).
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no specific intervention).
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Specific segmental muscle training program of the lumbar spine.
Number of subjects: 42
Study: 15025612

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with 5 mg of bupivacaine diluted with sterile water to 2.5-ml volume (SPIN-group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: General anaesthesia with spontaneous breathing via a laryngeal mask (GA-group)
Number of subjects: 70
Study: 10716136

Group type: EXPERIMENTAL
Intervention: E/O2 slope <27.6 and left ventricular ejection fraction >28% (n=18)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: E/O2 slope >27.6 and left ventricular ejection fraction >28% (n=12)
Number of subjects: 60
Study: 9307822

Group type: EXPERIMENTAL
Intervention: Sway magnetometry measurement before and after informing the subject that the test was starting (15 seconds before and 15 seconds after).
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sway magnetometry measurement for normal subjects and organic dizziness subjects.
Number of subjects: 47
Study: 8212757

Group type: EXPERIMENTAL
Intervention: 150 mg nizatidine nocte (n = 86)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: 2 x 150 mg/d nizatidine (n = 93)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: 2 x 300 mg/d nizatidine (n = 90)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: nizatidine 150 mg nocte (n = 116) in prophylactic trial
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: 2 x 150 mg nizatidine daily (n = 121) in prophylactic trial
Number of subjects: 269
Study: 3535187

Group type: COMPARATOR
Intervention: Daily short course chemotherapy (6-month) with regimens containing streptomycin, isoniazid, rifampicin, and pyrazinamide in the initial phase; isoniazid plus rifampicin or isoniazid plus rifampicin and/or pyrazinamide in the continuation phase.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily short course chemotherapy (6-month)
Number of subjects: 0
Study: 31318258

Group type: EXPERIMENTAL
Intervention: Perceived momentum in sequential events
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Events that break streaks (e.g., incorrect guesses)
Number of subjects: 0
Study: 31004325

Group type: EXPERIMENTAL
Intervention: Needle-free insulin injector
Number of subjects: 420

Group type: COMPARATOR
Intervention: Conventional insulin pen
Number of subjects: 420
Study: 28734823

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg daily for up to 28 days
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 142
Study: 26512232

Group type: EXPERIMENTAL
Intervention: Trial participation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Trust in family practitioner (FP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Safety concerning symptom relief
Number of subjects: 25

Group type: COMPARATOR
Intervention: Individual treatment preferences
Number of subjects: 25
Study: 23388664

Group type: EXPERIMENTAL
Intervention: Intense individualized dietary advice (dietetic follow-up fortnightly for 6 months)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 27
Study: 22069986

Group type: EXPERIMENTAL
Intervention: Autologous periosteum wrapping tendon allograft
Number of subjects: 68

Group type: COMPARATOR
Intervention: Simple tendon allograft
Number of subjects: 68
Study: 19631949

Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB) 150-600 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16720762

Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Surface Replacement Arthroplasty (SRA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (contralateral hip)
Number of subjects: 120
Study: 14668658

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation of the ramus communicans nerve (lesion group)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Lidocaine injection (control group)
Number of subjects: 49
Study: 11480533

Group type: EXPERIMENTAL
Intervention: Postpartum Depression Screening Scale (PDSS)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Beck Depression Inventory‐II (BDI‐II)
Number of subjects: 150
Study: 9267946

Group type: EXPERIMENTAL
Intervention: Dopexamine infusion at 6.0 microg/kg/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dopexamine infusion at 3.0 microg/kg/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dopexamine infusion at all rates (0.75, 1.5, 3.0, and 6.0 microg/kg/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control period (no dopexamine)
Number of subjects: 8
Study: 8305657

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (BCP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia (CCP)
Number of subjects: 100
Study: 3302866

Group type: EXPERIMENTAL
Intervention: Cefotaxime IV (100 mg.kg‐1 D‐1) plus netilmicin (4 mg.kg‐1 D‐1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid IV (100/10 mg.kg‐1 D‐1) plus netilmicin (4 mg.kg‐1 D‐1)
Number of subjects: 22
Study: 30352626

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neoadjuvant ipilimumab‐HDI
Number of subjects: 30
Study: 27269741

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg plus ipilimumab 1 mg/kg
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg
Number of subjects: 216
Study: 25129520

Group type: EXPERIMENTAL
Intervention: AUC-based educational intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 21996521

Group type: EXPERIMENTAL
Intervention: Nimorazole
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study: 20298924

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 4543

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4543
Study: 18680975

Group type: EXPERIMENTAL
Intervention: General anesthesia schemes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive therapy schemes
Number of subjects: 0
Study: 16422888

Group type: EXPERIMENTAL
Intervention: ACE inhibitor
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 12829908

Group type: EXPERIMENTAL
Intervention: Daclizumab 1 mg/kg immediately after liver transplantation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no induction therapy)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Daclizumab group
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 10791000

Group type: COMPARATOR
Intervention: Conventional full-dose docetaxel (FD) 60 mg/m2 every 3 or 4 weeks (group I)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-dose weekly docetaxel (LD) 20-30 mg/m2 every week (group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose weekly docetaxel (LD) 20-30 mg/m2 weekly with oral 5'-DFUR 600-1,200 mg per day (LD + D, group III)
Number of subjects: 60
Study: 8646099

Group type: EXPERIMENTAL
Intervention: Fundholding practices
Number of subjects: 108300

Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 108300
Study: 1513941

Group type: COMPARATOR
Intervention: PCADF (intravenous conventional PCA at fixed demand doses)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PCADV (demand doses varied according to pain intensity)
Number of subjects: 30

Group type: COMPARATOR
Intervention: PCAC + DV (continuous infusion with additional demand doses in variable bolus)
Number of subjects: 30
Study: 6390928

Group type: EXPERIMENTAL
Intervention: Cefoperazone (third-generation cephalosporin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30664524

Group type: EXPERIMENTAL
Intervention: Face mask
Number of subjects: 50

Group type: COMPARATOR
Intervention: HFNO
Number of subjects: 50
Study: 30407312

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 26610643

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 2502

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 2502
Study: 24253758

Group type: EXPERIMENTAL
Intervention: β‐glucan (BG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rye bread with kernels (RK)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: concentrated arabinoxylan (AX)
Number of subjects: 15

Group type: COMPARATOR
Intervention: refined wheat bread (WB)
Number of subjects: 15
Study: 22124880

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 28

Group type: COMPARATOR
Intervention: Water
Number of subjects: 28
Study: 20664343

Group type: EXPERIMENTAL
Intervention: Superpulsed low-level laser therapy (SLLLT)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs (ibuprofen 800 mg twice a day for 10 days)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sham laser (placebo)
Number of subjects: 99
Study: 17468357

Group type: EXPERIMENTAL
Intervention: CGMS/KADIS
Number of subjects: 49

Group type: COMPARATOR
Intervention: CGMS
Number of subjects: 49
Study: 15911687

Group type: EXPERIMENTAL
Intervention: Job social skills training
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Financial management skills training
Number of subjects: 92
Study: 12696648

Group type: EXPERIMENTAL
Intervention: Reconstitution of drinking water in the miners' workplace
Number of subjects: 150

Group type: COMPARATOR
Intervention: Before water reconstitution
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: After water reconstitution
Number of subjects: 150
Study: 9602222

Group type: EXPERIMENTAL
Intervention: Alcoholic solution under occlusion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Occlusion only
Number of subjects: 15

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 15
Study: 7747581

Group type: EXPERIMENTAL
Intervention: Lidocaine, bupivacaine, adrenaline and hyaluronidase
Number of subjects: 54

Group type: COMPARATOR
Intervention: Lidocaine and bupivacaine
Number of subjects: 54
Study: 2598475

Group type: EXPERIMENTAL
Intervention: Morphine administration
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 4685317

Group type: EXPERIMENTAL
Intervention: Mobilization on day 10
Number of subjects: 203

Group type: COMPARATOR
Intervention: Mobilization on day 20
Number of subjects: 203
Study: 31977567

Group type: EXPERIMENTAL
Intervention: Lanreotide autogel/depot 120 mg
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 31894027

Group type: EXPERIMENTAL
Intervention: Nifedipine controlled-release tablets combined with valsartan
Number of subjects: 180

Group type: COMPARATOR
Intervention: Valsartan dispersible tablets
Number of subjects: 180
Study: 28813218

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 2203

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 2203
Study: 25249172

Group type: EXPERIMENTAL
Intervention: Povidone iodine solution (0.5 mg/mL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 30
Study: 24050860

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT)
Number of subjects: 3755

Group type: COMPARATOR
Intervention: Double-dose clopidogrel dual antiplatelet therapy (DDAT)
Number of subjects: 3755

Group type: EXPERIMENTAL
Intervention: TAT
Number of subjects: 3755

Group type: COMPARATOR
Intervention: DDAT
Number of subjects: 3755

Group type: COMPARATOR
Intervention: TAT and DDAT
Number of subjects: 3755
Study: 21334061

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Adaptive Pacing Therapy (APT)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Specialist Medical Care (SMC)
Number of subjects: 641
Study: 19186714

Group type: EXPERIMENTAL
Intervention: Garlic moxibustion added to routine chemotherapeutic program
Number of subjects: 53

Group type: COMPARATOR
Intervention: Routine chemotherapeutic program of western medicine
Number of subjects: 53
Study: 16850682

Group type: EXPERIMENTAL
Intervention: 6 hour-supine recumbence
Number of subjects: 65

Group type: COMPARATOR
Intervention: Early ambulation (<= 1 hour)
Number of subjects: 65
Study: 14691381

Group type: EXPERIMENTAL
Intervention: Socially anxious individuals
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nonsocially anxious controls
Number of subjects: 46
Study: 10882444

Group type: EXPERIMENTAL
Intervention: Bioabsorbable interference screw for femoral fixation and titanium interference screw for tibial fixation (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Titanium interference screws for both femoral and tibial fixation (Group B)
Number of subjects: 40
Study: 8769360

Group type: EXPERIMENTAL
Intervention: Full-fat group
Number of subjects: 68

Group type: COMPARATOR
Intervention: Reduced-fat group
Number of subjects: 68
Study: 1576630

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (I-C)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Clindamycin+aminoglycoside (C+A)
Number of subjects: 49
Study: 3930683

Group type: EXPERIMENTAL
Intervention: Oral administration of 1-[13C]acetate
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Rectal administration of 1-[13C]acetate
Number of subjects: 5
Study: 3806876

Group type: EXPERIMENTAL
Intervention: Low serum cholesterol level
Number of subjects: 361662

Group type: EXPERIMENTAL
Intervention: Annual measurements of serum cholesterol level in the randomized trial
Number of subjects: 361662

Group type: COMPARATOR
Intervention: High serum cholesterol level
Number of subjects: 361662
Study: 31514191

Group type: EXPERIMENTAL
Intervention: Physiotherapy plus intra-articular methylprednisolone injection
Number of subjects: 52

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 52
Study: 29143570

Group type: EXPERIMENTAL
Intervention: High-velocity, low-load (40% of predicted one repetition maximum)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-velocity, high-load (80% of predicted one repetition maximum)
Number of subjects: 10
Study: 28333482

Group type: EXPERIMENTAL
Intervention: Interim test group (completed a recall test after each list)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No interim test group (only tested on the final list)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interim test group
Number of subjects: 0
Study: 26248726

Group type: EXPERIMENTAL
Intervention: Standard care plus a glaucoma personal record detailing the current state of their condition
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard clinical care (control arm)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Standard care plus a glaucoma personal record
Number of subjects: 122
Study: 23970941

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (8 ounces daily for 4 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo drink (flavor-matched, 8 ounces daily for 4 weeks)
Number of subjects: 32
Study: 21420053

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate plus sodium chloride (bicarbonate group, n = 78)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Sodium chloride alone (chloride group, n = 77)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate plus sodium chloride (bicarbonate group)
Number of subjects: 155
Study: 18656300

Group type: EXPERIMENTAL
Intervention: Chest compression-only CPR
Number of subjects: 223

Group type: COMPARATOR
Intervention: Conventional CPR
Number of subjects: 223
Study: 16141376

Group type: EXPERIMENTAL
Intervention: H2-receptor antagonist (300 mg oral ranitidine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no ranitidine)
Number of subjects: 10
Study: 14603191

Group type: EXPERIMENTAL
Intervention: Microthrombectomy in group 1 (veins 1 mm or less)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control side in group 1 (veins 1 mm or less)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Microthrombectomy in group 2 (veins 3 mm or less)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control side in group 2 (veins 3 mm or less)
Number of subjects: 101
Study: 10848875

Group type: EXPERIMENTAL
Intervention: Lipid‐heparin emulsion (Li‐He, Intralipid 10% 250 ml + heparin 2500 U iv from ‐60 to + 90 minutes)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acipimox (ACI, 250 mg p.o. at ‐60 minutes)
Number of subjects: 15